We conducted a phase II study of personalized peptide vaccination (PPV) for 46 patients with advanced small cell lung cancer (SCLC). We observed immune boosting and possible prolongation of overall survival after PPV without severe adverse events. These results suggest that PPV has potential as a new treatment modality for SCLC. Introduction: The prognosis of patients with small cell lung cancer (SCLC) remains very poor. Therefore, the development of new therapeutic approaches, including immunotherapies, is desirable. Patients and Methods: We conducted a phase II study of personalized peptide vaccination (PPV), in which a maximum of 4 human leukocyte antigen-matched peptides were selected from 31 pooled peptides according to the pre-existing peptide-specific IgG responses before vaccination. The PPV was subcutaneously administered. Results: Forty-six patients were enrolled (median age, 63 years; 40 patients were men). Grade 1 (n ¼ 13), 2 (n ¼ 10), or 3 (n ¼ 1) skin reactions at the injection sites were observed; however, no other severe adverse events related to the PPV were observed. The median survival time was 466, 397, 401, and 107 days in the subgroups with 0 (n ¼ 5), 1 (n ¼ 15), 2 (n ¼ 12), and 3 (n ¼ 14) previous chemotherapy regimens, respectively. Peptide-specific IgG responses to the vaccinated peptides were augmented in 70% and 95% of patients after 1 and 2 vaccination cycles, respectively. The overall survival (OS) of patients with augmented IgG responses to a greater number of nonvaccinated peptides after the second cycle of vaccination was significantly longer (median survival time, 1237 days vs. 382 days; P ¼ .010). In addition, augmentation of IgG responses specific to 6 peptides, including Lck-derived peptides, was significantly related to better OS (P < .05, in each peptide). Conclusion: These results suggest the feasibility of PPV for SCLC patients from the viewpoints of safety, immune boosting, and possible prolongation of OS. Therefore, further evaluation of PPV for advanced SCLC in prospective randomized trials is warranted.
Introduction
Lung cancer is the leading cause of cancer-related deaths globally, and small cell lung cancer (SCLC) accounts for approximately 13% of all lung cancer cases. 1 SCLC is an aggressive neuroendocrine malignancy and has features of a short doubling time, high growth fraction, and early development of widespread metastases. 2 Therefore, patients with SCLC have a very poor prognosis. Moreover, although many clinical trials of targeted therapies and newer chemotherapeutic agents have been conducted, no effects were obtained compared with standard therapy. 2 Thus, a need exists for newer therapeutic approaches. One such approach might be blockade of the T-cell inhibition mediated by the checkpoint molecules, such as programmed death 1 and programmed death ligand 1, in SCLC patients, because the expression of programmed death ligands 1 and 2 has been observed in the tumor microenvironment of SCLC. 3 Another new approach might be personalized therapeutic agents. Along this line, we developed a novel regimen of personalized peptide vaccination (PPV), in which peptides are selected and administered according to the pre-existing host immunity before vaccination. In the present study, we investigated the feasibility of PPV for SCLC patients.
Patients and Methods

Patients
Patients with a diagnosis of advanced SCLC were eligible for the present study. All patients were required to have a diagnosis of limited-stage SCLC, extensive-stage SCLC, or recurrent-atdiagnosis disease. In addition, the patients were required to have positive IgG responses to 2 of the 31 different vaccine candidate peptides, as reported previously. [4] [5] [6] The other inclusion criteria
were Eastern Cooperative Oncology Group performance status of 0 or 1 at the first visit, positive status for human leukocyte antigen (HLA)-A2, -A24, -A3 supertype (A3, A11, A31, or A33), or -A26 types, life expectancy of 12 weeks, and adequate hematologic, hepatic, and renal function. The exclusion criteria were pulmonary, cardiac, or other systemic diseases; acute infection; a history of severe allergic reactions; pregnancy or nursing; and other inappropriate conditions for enrollment as judged by the clinicians. The Kurume University and Sendai Kousei Hospital ethical committees approved the protocol, which was registered in the University Hospital Medical Information Network (UMIN) Center Clinical Trials Registry (UMIN nos. 1482, 1839, 2984, 6927, 10068, and 11230). All patients were given a full explanation of the protocol and provided their informed consent before enrollment.
Clinical Protocol
We performed a phase II study to evaluate the safety, immunologic responses, and clinical benefits with the endpoint of overall survival (OS) in advanced SCLC patients receiving PPVs. We used 31 peptides for vaccination (12 peptides for HLA-A2, 16 peptides for HLA-A24, 9 peptides for HLA-A3 supertypes [HLA-A3, -A11, -A31, and -A33], and 4 peptides for HLA-A26), as previously reported (Supplemental Table 1 ; online version). [4] [5] [6] These peptides were prepared in accordance with the conditions of Good Manufacturing Practice by PolyPeptide Laboratories (San Diego, CA) and American Peptide Company (Vista, CA). The peptides for vaccination of individual patients were selected by considering the pre-existing host immunity before vaccination, as assessed by the titers of IgG specific to each of the 31 different vaccine candidates.
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A maximum of 4 peptides (3 mg/each peptide), which were selected according to the results of HLA typing and peptide-specific IgG titers, were subcutaneously administered with incomplete Freund's adjuvant (Montanide ISA51; Seppic, Paris, France). Feasibility Study of PPV for Advanced SCLC We used 3 different regimens for the number and interval of peptide administration, based on the different protocols (Figure 1) . The PPV were administered 6 times weekly (UMIN nos. 1482, 1839, and 10068), 4 times weekly followed by 4 times every 2 weeks (UMIN no. 2984), or 4 times every 4 weeks (UMIN nos. 6927 and 11230) for the first cycle. In UMIN protocols 6927 and 11230, the amount of peptides was doubled (6 mg of each peptide). After the first cycle of vaccinations, 4 antigen peptides were reselected according to the titers of peptide-specific IgG. At the second cycle, the peptides were administered 6 times every 2 weeks (UMIN nos. 1482, 1839, and 10068), 8 times every 4 weeks (UMIN no. 2984), or 4 times every 4 weeks (UMIN nos. 6927 and 11230). At subsequent cycles of vaccinations, 4 peptides that were again reselected were administered every 4 to 6 weeks. During PPV, the patients were permitted to receive combination therapies, such as chemotherapy or radiotherapy. Adverse events were monitored according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0. Complete blood counts and serum biochemistry tests were performed before and after each cycle of PPV. Tumor assessments by computed tomography or magnetic resonance imaging were performed before and after PPV, and the findings were evaluated using the Response Evaluation Criteria In Solid Tumors, version 1.1.
Measurement of IgG Response
Humoral immune responses specific to each of the 31 peptide candidates were determined by peptide-specific IgG levels using the Luminex system (Luminex, Austin, TX), as previously reported. [12] [13] [14] [15] If the titers of peptide-specific IgG to 1 of the vaccinated peptides after vaccination (at the end of the first or second cycle) were more than twofold greater than those in the prevaccination plasma, the changes were considered to be significant, as previously reported.
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Statistical Analysis
OS was calculated from the first day of PPV to the date of death or the last date when the patient was known to be alive. The survival analysis was performed using the Kaplan-Meier method, and a comparison of the survival curves was performed using the log-rank test. If the P value was < .05, the difference was considered statistically significant. All statistical analyses were conducted using JMP, version 12 (SAS Institute Inc, Cary, NC). received no previous therapy. When the patients were divided into 4 subgroups according to the number of previously conducted chemotherapy regimens, a significant difference in patient characteristics was observed only for the stage at diagnosis. During PPV, 32 patients were treated in combination with chemotherapy, and 14 patients received no combination therapy. In these 14 patients, the number of previously conducted chemotherapy regimens was 0 for 2, 1 for 5, 2 for 2, and 3 for 5. The number of patients who completed the first and second cycle of PPVs was 33 and 21, respectively; 13 patients did not complete the first cycle because of rapid disease progression. 
Metabolic and laboratory
Skin and subcutaneous tissue disorder
Data presented as n (%). Abbreviations: ALP ¼ alkaline phosphatase; ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; PPV ¼ personalized peptide vaccination.
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Adverse Events
The severe adverse events (SAEs) that occurred during the study period are listed in Table 2 . Grade 1 (n ¼ 21), 2 (n ¼ 12), and 3 (n ¼ 1) skin reactions at the injection sites were observed. Other grade 3 or 4 SAEs were observed in some patients. However, none were found to be directly associated with PPV but instead were associated with the disease progression or combination therapy according to evaluation by the independent safety evaluation committee.
IgG Responses to Vaccine Peptides
Peptide-specific IgG responses were analyzed in blood samples before and after the first and second cycle of vaccination. The levels of peptide-specific IgGs reactive to each of the 31 different peptides, including the vaccinated and nonvaccinated peptides, were measured using a Luminex system. The IgG responses before vaccination were well observed in all the patients. IgG responses specific to 1 of the vaccinated peptides had increased after the first cycle of vaccination in 23 of 33 patients (70%) and after the second cycle of vaccination in 20 of 21 patients (95%) tested (Table 3) . We also evaluated the IgG levels specific to nonvaccinated peptides in plasma before and after the first and second cycle of vaccination. The results showed that increases in IgG levels specific to 1 of the nonvaccinated peptides occurred after the first cycle of vaccination in 24 of 33 patients (73%) tested and after the second cycle of vaccination in all 21 patients tested (Supplemental Table 2 ; online version). The median number of nonvaccinated peptides exhibiting an increase in specific IgG levels after the first or second cycle of vaccination was 6.5 or 12.5 peptides, respectively.
Overall Survival
The median survival time (MST) for all patients from the first PPV cycle was 285 days (95% confidence interval [CI], 195-401 days; Figure 2A ). When the patients were grouped by the number of previously conducted chemotherapy regimens, the MST was 466, If the titers of peptide-specific IgG at the end of first or second cycle were more than twofold greater than those in prevaccination plasma or were newly apparent, these changes were considered enhanced. Figure 2B ). No significant differences in OS were observed between the patients with and without augmentation of IgG responses specific to 1 of the vaccinated peptides after the first and second cycle of vaccination (P ¼ .89 and P ¼ .25, respectively; data not shown). Next, we divided the patients into 2 subgroups according to the median number of nonvaccinated peptides exhibiting an increase in specific IgG levels after the first or second cycle of vaccination and compared the OS in the 2 subgroups. Although no significant difference was observed after the first cycle (P ¼ .46; Figure 2C ), the results of the log-rank test showed that patients with IgG responses to a larger number of nonvaccinated peptides after the second cycle of vaccination had longer OS (P ¼ .01; Figure 2D ). We also compared the OS between patients with and without augmentation of IgG responses specific to each of 31 peptides after the second cycle of vaccination. A significant difference by log-rank test was observed for the following 6 peptides: MAP-432, Lck-208, MRP3-1293, SART2-161, Lck-90, and Lck-449 (Figure 3) . However, for the remaining 25 peptides, no significant differences were observed (data not shown).
Clinical Response
The best clinical responses were evaluated in 44 patients whose radiologic findings were available before and after PPV. No patient experienced a complete response, 2 patients had a partial response, 15 patients had stable disease, and 27 had progressive disease. Two patients with a partial response and 11 with stable disease had been treated with a combination of PPV and chemotherapy.
Discussion
The results of the present study have demonstrated a potential clinical benefit of PPV for SCLC patients. The MST of the patients without a response to 1 or 2 chemotherapy regimens before PPV was 397 or 401 days, respectively. Because recent reports have shown that the MST of SCLC patients after failure of 1 or 2 regimens is 225 to 234 days or 141 days, respectively, it might be possible that PPV prolonged the OS of patients with advanced SCLC. 18 However, in the present study, it was difficult to consider the possible clinical benefit for the patients who had never received standard therapy before PPV, because the number of patients was too small (n ¼ 5), and 2 of the 5 patients did not receive standard chemotherapy combined with PPV. Regarding the occurrence of adverse events, grade 1, 2, or 3 injection site reactions were observed in 74% of the patients. Although other SAEs were also seen in some patients, these other SAEs were not directly associated with PPV but with disease progression or the receipt of combined therapy. These results were consistent with previously reported results for PPV for patients with other cancer types. 7, 8 Concerning the PPV-mediated immune responses, augmentation of IgG responses to vaccinated peptides was observed in 70% and 95% of patients after the first and second cycle of vaccination, respectively. We previously reported that augmentation of IgG responses to vaccinated peptides correlates well with OS. 14, 15 In the present study, however, we found no significant differences in OS between the patients with and without augmentation of IgG responses to vaccinated peptides after the first or second cycle of vaccination. This discrepancy might have been resulted from the frequency of immunologic boosting in the SCLC patients in our study, which was greater than that observed in previous studies of other cancer types, or might have simply resulted from the small number of patients tested in our study. Cellular immune responses, such as cytotoxic T-lymphocyte (CTL) responses, were not measured in the present study. Because we have shown that increased CTL responses against vaccinated peptides were significantly associated with increased peptide-specific IgG responses after the first cycle of vaccination, the peptide-specific CTL responses could also be expected to be augmented. 19 Similar to the IgG responses specific to vaccinated peptides, augmentation of IgG responses specific to nonvaccinated peptides was also observed in most patients in the present study, especially after the second cycle of vaccination (21 of 21 patients; 100%). We previously reported that the presence of IgG responses to nonvaccinated peptides was a favorable factor for OS.
14 Because IgG responses to nonvaccinated peptides were observed in most patients in the present study, it was difficult to assess the relationship between IgG responses to nonvaccinated peptides and OS. Nevertheless, the patients with IgG responses to a larger number of nonvaccinated peptides after the second cycle of vaccination experienced significantly longer OS in the present study (1237 days vs. 382 days; P ¼ .01). The increase in IgG responses to nonvaccinated peptides might be explained by the concept of "epitope spreading"; however, further studies are required to clarify its mechanism. In addition, we evaluated whether the augmentation of IgG responses to specific peptides was associated with an improvement in the prognosis. A significant difference in OS was observed for 6 of the 31 peptides used in the present study. Of these 31 peptides, 3 were derived from Lck. Although Lck, an src family tyrosine kinase, is known to be essential for both T-cell development and function, it has also been reported to be aberrantly expressed in SCLC and other cancer types, in particular, in metastatic cancer cells rather than primary cancer cells. 20, 21 Because SCLC is characterized by the early development of widespread metastases, which might frequently express the Lck protein, it is possible that immune responses specific to Lck could show antitumor activity and a better therapeutic effect for metastatic cancer cells. The present study had shortcomings and limitations. Because ours was a small study with a limited number of patients with various characteristics, we could not perform detailed and precise analysis by considering each patient's characteristics, such as the number of previously conducted chemotherapy regimens or the use of combination therapies. Therefore, the clinical efficacy of PPV in each subgroup of SCLC patients remains to be investigated in future larger scale studies.
Conclusion
The present study has suggested the feasibility of PPV as a new treatment modality for SCLC, with positive findings for the safety profile, immune boosting, and possible prolongation of OS. Further evaluation of PPV in prospective randomized trials are recommended for SCLC. In addition, the results of the present study suggest that augmented immune responses to specific peptides, such as Lck-derived peptides, might be associated with improved prognosis. Because it might be possible to render PPV more effective by selecting such specific peptides, further detailed study of each peptide in SCLC is needed.
Clinical Practice Points
SCLC has the features of a short doubling time, high growth fraction, and early development of widespread metastases and portends a very poor prognosis. Moreover, although many clinical trials of targeted therapies and newer chemotherapeutic agents have been conducted, no beneficial effects have been found compared with standard therapy. We developed a PPV, in which a maximum of 4 HLA-matched peptides were selected from among 31 pooled peptides according to the pre-existing host immunity before vaccination; the PPV is administered subcutaneously. We conducted a phase II study of PPV for SCLC patients; PPV increased peptide-specific IgG responses without severe adverse events, except in the case of 1 patient with grade 3 skin reactions at the injection sites. Moreover, we observed possible prolongation of OS, especially for the patients with IgG responses specific to a larger number of nonvaccinated peptides and augmentation of IgG responses specific to 6 peptides, such as Lck-derived peptides. The results of the present study have shown that PPV has potential as a new treatment modality for SCLC patients. Therefore, further evaluation of PPV for SCLC patients in prospective randomized trials is warranted.
